Analysis of Oxidative Stress Biomarkers and Their Determinants in ART-experienced PLWH
NCT ID: NCT05760495
Last Updated: 2023-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
543 participants
OBSERVATIONAL
2022-09-02
2023-05-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression
NCT01613157
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
NCT02836782
Pharmacogenetics of Antiretroviral Drugs
NCT00435656
Observational Study on Patients With HIV/AIDS(OSPWH)
NCT04667026
Analysis of HIV-1 Replication During Antiretroviral Therapy
NCT00767312
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single arm
ART-experienced PLWH
blood sampling
Blood sampling for evaluation of oxidative stress markers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling
Blood sampling for evaluation of oxidative stress markers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV-1 RNA\< 50 copies/mL
* Stable ART therapy (at least 48 weeks)
* Signature of informed consent for study participation
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Francesca Lombardi
Roma, RM, Italy
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4477
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.